Mounjaro Kwikpen 12.5mg/0.6ml Lilly 2.4ml

INCLUDES 32G x 4MM NEEDLES WITH EVERY ORDER

Mounjaro 12.5mg/0.6ml is a prescription only medicine indicated for:

– the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy or in addition to other medicinal products.

– weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of

• ≥ 30 kg/ m2 (obesity) or
• ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).

Mechanism of action:

Tirzepatide is a long-acting dual GIP and GLP-1 receptor agonist. Both receptors are present on the pancreatic α and β endocrine cells, heart, vasculature, immune cells (leukocytes), gut and kidney. GIP receptors are also present on adipocytes.

In addition, both GIP and GLP-1 receptors are expressed in the areas of the brain important to appetite regulation. Tirzepatide is highly selective to human GIP and GLP-1 receptors. Tirzepatide has high affinity to both the GIP and GLP-1 receptors.

Tirzepatide lowers body weight and body fat mass. The mechanisms associated with body weight and body fat mass reduction involve decreased food intake through the regulation of appetite and modulation of fat utilisation.

Contraindications:

Hypersensitivity to the active substance or to any of the excipients.

Store in a refrigerator at 2–8°C. 5 needles included with every order.

Mounjaro Kwikpen 2.5mg/0.6ml has an official MRHA extension to February 2025 with paperwork of proof.

EMC: https://www.medicines.org.uk/emc/product/15481/smpc#about-medicine

Patient Information Leaflet: https://www.medicines.org.uk/emc/files/pil.15481.pdf

User manual: https://www.medicines.org.uk/emc/files/usermanual.15481.pdf